SABCS 2018 — Lifestyle intervention improves weight loss after chemotherapy


  • Tara Haelle
  • Univadis
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • An intensive 2-year lifestyle intervention program for moderate weight loss was associated with increased DFS in program completers, according to data from the phase 3 SUCCESS C trial.

Why this matters

  • Obesity and reduced physical activity are associated with increased breast cancer incidence, increased recurrence, and decreased survival. 

Study design

  • 2292 women with breast cancer and a BMI ≥24 kg/m2 were randomly assigned after chemotherapy to receive either general healthy lifestyle advice through mailings/newsletters (n=1146) or personalized telephone- and mail-based guidance aimed at long-term moderate weight loss (n=1146).
  • Multivariable aHRs were adjusted for age, BMI, menopausal status, tumor size, nodal stage, HR status, grading, histological type, and chemotherapy randomization.
  • Funding: Chugai; GlaxoSmithKline; Janssen Diagnostics; Pfizer; Sanofi-Aventis.

Key results

  • Median follow-up, 64.2 months.
  • Women in the intervention group lost a mean 1 kg (n=828) compared with a mean 0.95 kg gain in control patients (n=816; P
  • Intent-to-treat analysis showed no difference in DFS (HR, 0.99 [P=.922]; aHR, 0.91 [P=.48]) or OS (P=.799).
  • 1477 patients completed the program.
    • Intervention completers (n=552) had significantly greater DFS than noncompleters (n=594; HR, 0.35; P<.001>
    • Intervention completers had significantly greater DFS than control group completers (n=925; HR, 0.53 [P=.004]; aHR, 0.51 [P=.002]).

Limitations 

  • Low adherence to intervention.
  • Low number of events.
  • Study completers may have had greater motivation.